Sökning: WFRF:(Henrohn Dan) >
Acute vasodilator r...
Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension
-
- Sandqvist, Anna, 1980- (författare)
- Umeå universitet,Farmakologi,Umea Univ, Div Clin Pharmacol, Dept Pharmacol & Clin Neurosci, Umea, Sweden.
-
- Henrohn, Dan (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Egeröd, Hanna (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
visa fler...
-
- Hedeland, Mikael (författare)
- Uppsala universitet,Avdelningen för analytisk farmaceutisk kemi,Natl Vet Inst SVA, Dept Chem, Uppsala, Sweden.
-
- Wernroth, Lisa (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
- Bondesson, Ulf (författare)
- Uppsala universitet,Avdelningen för analytisk farmaceutisk kemi,Natl Vet Inst SVA, Dept Chem, Uppsala, Sweden.
-
- Schneede, Jörn (författare)
- Umeå universitet,Farmakologi,Umea Univ, Div Clin Pharmacol, Dept Pharmacol & Clin Neurosci, Umea, Sweden.
-
- Wikström, Gerhard (författare)
- Uppsala universitet,Kardiologi
-
visa färre...
-
(creator_code:org_t)
- 2015-08-05
- 2015
- Engelska.
-
Ingår i: European Journal of Clinical Pharmacology. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 71:10, s. 1165-1173
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Acute vasodilator testing is recommended in patients with pulmonary arterial hypertension to identify individuals who may benefit from long-term treatment with oral calcium channel blockers. The aim of this study was to investigate the use of vardenafil in acute vasoreactivity testing compared to adenosine.METHODS: A total of 20 patients eligible for right heart catheterisation were enrolled. Acute vasoreactivity testing was carried out with intravenous (iv) adenosine (n = 18) followed by oral vardenafil (n = 20). Haemodynamic responses were recorded at baseline and after 60 min (vardenafil). Responders were defined according to consensus guideline criteria.RESULTS: Both vardenafil and adenosine significantly decreased mean pulmonary arterial pressure (mPAP, p < 0.001 and p = 0.026, respectively) and pulmonary vascular resistance (p < 0.001 and p > 0.001, respectively), and significantly increased cardiac output (p = 0.001 and p = 0.005, respectively). Vardenafil reduced mPAP more than adenosine (p = 0.044), while adenosine resulted in higher responses of cardiac index (p = 0.009) and pulmonary arterial oxygen saturation (p = 0.042). Acute adverse reactions were common with adenosine, while no side effects were observed after a single oral dose vardenafil. Vardenafil identified five responders (out of 20), while adenosine identified three responders (out of 18). During a 7-year follow-up, vardenafil responders had significantly lower NT-proBNP levels compared to non-responders.CONCLUSIONS: Vardenafil may be safely used for acute vasoreactivity testing in patients with PH. A single oral dose of vardenafil is better tolerated than iv adenosine and may identify additional responders who could benefit from long-term vasodilator treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- denosine
- Vardenafil
- Acute vasodilator test
- Haemodynamics
- Pulmonary hypertension
- Right heart catheterisation
- kardiologi
- Cardiology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas